Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cardiothoracic Surgery
Published in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01-12-2024 | Neuroendocrine Tumor | Research

Analysis of 25 surgical cases of thymic neuroendocrine tumors and thymic carcinoma

Authors: Kensuke Midorikawa, So Miyahara, Nanako Nishino, Yuichirou Ueda, Ryuichi Waseda, Takeshi Shiraishi, Toshihiko Sato

Published in: Journal of Cardiothoracic Surgery | Issue 1/2024

Login to get access

Abstract

Background

The purpose of this study was to evaluate the clinicopathological characteristics of patients who underwent surgical resection for thymic neuroendocrine tumors (TNET) or thymic carcinoma.

Methods

In this study, we retrospectively evaluated the clinicopathological characteristics of our surgical patients at Fukuoka University Hospital from January 1995 to December 2018.

Results

There were nine cases of TNET and 16 cases of thymic carcinoma. Regarding the pathological type, the TNET group included three atypical carcinoid cases, two large cell neuroendocrine tumor cases, two small cell carcinoma cases, and two other cases. The thymic carcinoma group included 15 squamous carcinoma cases and one case of adenosquamous carcinoma. Based on the Masaoka-Koga staging system, six TNET cases and 11 thymic carcinoma cases were stage III or IV. The complete resection rate was 77% in the TNET group and 81% in the thymic carcinoma group. Additional chemotherapy and/or radiotherapy was performed in five cases of TNET and 11 cases of thymic carcinoma. The five-year survival rate and five-year disease-free survival rate were 87.5% and 75.0% in the TNET group and 58.9% and 57.1% in the thymic carcinoma group, respectively, with no significant difference between the two groups (P = 0.248 and P = 0.894, respectively). In the univariate analysis, complete resection was a statistically significant prognostic factor (P = 0.017).

Conclusion

In this study, no difference in prognosis was observed between TNET and thymic carcinomas. To understand the characteristics of these tumors, further case accumulation and multicenter clinical studies are needed. (243words)
Literature
1.
Cardillo G, Rea F, Lucchi M, Paul MA, Margaritora S, Carleo F, et al. Primary neuroendocrinetumors of the thymus: a multicenter experience of 35 patients. Ann Thorac Surg. 2012;94:241–5.CrossRefPubMed
2.
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, et al. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the international thymic malignancy interest group and the European Society of thoracic surgeons databases. J Thorac Cardiovasc Surg. 2015;149:103–9.CrossRefPubMed
3.
Marx A, Shimosato Y, Kuo TT, Chan JK, Travis WD, Wick WR, et al. Thymic neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumours: Pathology and Genetics of tumours of the lung, Pleura, Thymus and heart. Lyon: IARC; 2004. pp. 188–95.
4.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, Fourth Edition. France: International Agency for Research on Cancer.2015;234–242.
5.
WHO Classification of Tumours Editorial Board. Thoracic tumours. WHO classification of Tumours. Fifth Edition. ed. Lyon, France: International Agency for Research on Cancer; 2021.
6.
Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359–67.CrossRefPubMed
7.
Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2010;5:2017–23.CrossRefPubMed
8.
NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas, Version 1. (2022) Online: www.​nccn.​org [accessed May 20, 2022].
9.
NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors, Version 1. (2022) Online: www.​nccn.​org [accessed May 20, 2022].
10.
Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67:1025–32.CrossRefPubMed
11.
Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol. 2000;114:100–10.CrossRefPubMed
12.
Ströbel P, Zettl A, Shilo K, Chuang WY, Nicholson AG, Matsuno Y, et al. Tumor genetics and survival of thymic neuroendocrine neoplasms: a multiinstitutional clinicopathologic study. Genes Chromosomes Cancer. 2014;53:738–49.CrossRefPubMed
13.
Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw P. A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest. 2003;124:141–6.CrossRefPubMed
14.
Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76:878–85.CrossRefPubMed
15.
Weksler B, Holden A, Sullivan JL. Impact of positive nodal metastases in patients with Thymic Carcinoma and thymic neuroendocrine tumors. J Thorac Oncol. 2015;10:1642–7.CrossRefPubMed
16.
Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, et al. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. Eur J Cardiothorac Surg. 2016;50:766–71.CrossRefPubMedPubMedCentral
17.
Zhao Y, Gu H, Fan L, Han K, Yang J, Zhao H. Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients. Eur J Cardiothorac Surg. 2017;52:33–8.CrossRefPubMed
18.
Wen J, Chen J, Chen D, Liu D, Xu X, Huang L, et al. Evaluation of the prognostic value of surgery and postoperative radiotherapy for patients with thymic neuroendocrine tumors: a propensity-matched study based on the SEER database. Thorac Cancer. 2018;9:1603–13.CrossRefPubMedPubMedCentral
19.
Song Q, Zhang LL, Qi Y, Xing KL, Wu XH. Effect of clinicopathologic features on survival of patients with thymic carcinomas and thymic neuroendocrine tumors: a population-based analysis. Curr Probl Cancer. 2019;43:411–20.CrossRefPubMed
20.
Bakhos CT, Salami AC, Kaiser LR, Petrov RV, Abbas AE. Thymic neuroendocrine tumors and thymic carcinoma: demographics, treatment, and Survival. Innovations. 2020;15:468–74.PubMed
21.
Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011;6:1698–704.CrossRef
22.
Sullivan JL, Weksler B. Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients. Ann Thorac Surg. 2017;103:935–9.CrossRefPubMed
23.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, et al. Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma. Interact Cardiovasc Thorac Surg. 2020;31:98–101.CrossRefPubMed
24.
Song Z, Zhang Y. Primary neuroendocrine tumors of the thymus: clinical review of 22 cases. Oncol Lett. 2013;8:2125–9.CrossRef
25.
Fukai I, Masaoka A, Fujii Y, Yamakawa Y, Yokoyama T, Murase T, et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg. 1999;67:208–11.CrossRefPubMed
26.
Filosso PL, Ruffini E, Solidoro P, Roffinella M, Lausi PO, Lyberis P, et al. Neuroendocrine tumors of the thymus. J ThoracDis. 2017;9:1484–90.CrossRef
27.
Takei H, Kondo H, Miyaoka E, Asamura H, Yoshino I, Date H, et al. Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol. 2014;9:1140–5.CrossRefPubMed
28.
Cardillo G, Treggiari S, Paul MA, Carleo F, De Massimi AR, Remotti D, et al. Primary neuroendocrine tumors of the thymus: a clinico pathologic and prognostic study in 19 patients. Eur J Cardiothorac Surg. 2010;37:814–8.CrossRefPubMed
29.
de Montpréville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg. 1996;111:134–41.CrossRefPubMed
30.
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, European Society of Thoracic Surgeons Thymic Group Steering Committee, et al. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of thoracic surgeons databases. J Thorac Cardiovasc Surg. 2015;149:103–9.CrossRefPubMed
31.
Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29:2060–5.CrossRefPubMedPubMedCentral
32.
Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26:363–8.CrossRefPubMed
33.
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicenter, phase 2 trial. Lancet Oncol. 2020;21:843–50.CrossRefPubMed
34.
Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-center, phase 2 study. Lancet Oncol. 2018;19:347–55.CrossRefPubMedPubMedCentral
35.
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162–70.CrossRefPubMed
Metadata
Title
Analysis of 25 surgical cases of thymic neuroendocrine tumors and thymic carcinoma
Authors
Kensuke Midorikawa
So Miyahara
Nanako Nishino
Yuichirou Ueda
Ryuichi Waseda
Takeshi Shiraishi
Toshihiko Sato
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2024
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02723-w

Other articles of this Issue 1/2024

Journal of Cardiothoracic Surgery 1/2024 Go to the issue

Case Report

Successful Implantation of Rapid Deployment Aortic Valve after TAVR Explantation

Case Report

Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

Research

Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis

Research

A visceral organ function-focused therapeutic strategy using a 6-hour time window for patients with acute type a aortic dissection complicated by mesenteric malperfusion

Case Report

Unusual origins of cardiac insufficiency: a case of iliac arteriovenous fistula post-spinal disc surgery

Research

Short- and Long-term survival prediction in patients with acute type A aortic dissection undergoing open surgery